RT Journal Article
SR Electronic
T1 Preventing herpes zoster through vaccination: New developments
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 359
OP 366
DO 10.3949/ccjm.84a.16020
VO 84
IS 5
A1 Phuc Le
A1 Camille Sabella
A1 Michael B. Rothberg
YR 2017
UL http://www.ccjm.org/content/84/5/359.abstract
AB Herpes zoster (HZ) affects 1 million Americans every year. The disease burden is higher in immunocompromised patients. The live-attenuated HZ vaccine is effective in preventing HZ and postherpetic neuralgia and has been recommended for immunocompetent adults age 60 and older. However, because protection wanes by 10 years, a booster may be necessary. In 2015, an adjuvanted subunit HZ vaccine was shown to reduce incidence by 97%, even in the elderly, but long-term data on vaccine protection are not available. Clinical trials are under way to investigate a safe and effective vaccine for immunocompromised patients.